5712 Results

People

  1. Drilon
    Drilon
  2. Perales
    Perales
  3. Giralt
    Giralt
  4. Motzer
    Motzer
  5. Ladanyi
    Ladanyi
  6. Morrow
    Morrow
  7. Rimner
    Rimner
  8. O'Reilly
    O'Reilly
  9. Horwitz
    Horwitz
  10. Jones
    Jones

Groups

  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)
  7. Hematologic Malignancies, Division of (875)
  8. Center for Hematologic Malignancies (802)
  9. Population Sciences Research Program (786)
  10. Department of Pathology and Laboratory Medicine (677)
  1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1
    Meeting Abstract

    Sebag, M.; Raje, N. S.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • High rates of remission with the initial treatment of oral azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL): Clinical outcomes and biomarker analysis of a multi-center phase II study
    Meeting Abstract

    Ruan, J.; Moskowitz, A. J.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Rahim, R.; Song, W.; Kotlov, N.; Nos, G.; Maksimov, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Samaniego, F.; Burke, J. M.; Mahadevan, D.; Cherry, M.; Sadiq, A. A.; Koontz, M. Z.; Villasboas, J. C.; Reid, E.; Cull, E.; Priego, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy comparison of tisagenlecleucel versus standard of care in patients with relapsed or refractory follicular lymphoma
    Meeting Abstract

    Salles, G.; Schuster, S. J.; Dreyling, M. H.; Fischer, L.; Kuruvilla, J.; Patten, P. E. M.; Von Tresckow, B.; Smith, S. M.; Ubieto, A. I. J.; Davis, K. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Monoclonal gammopathy of undetermined significance and COVID-19: Results from the population-based Iceland screens treats or prevents multiple myeloma study (iStopMM)
    Meeting Abstract

    Rögnvaldsson, S; Eythorsson, E.; Thorsteinsdottir, S.; Vidarsson, B.; Onudarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Horsteinsdottir, I.; Olafsson, I.; Runolfsdottir, H. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Single-cell multi-omics reveals that pegylated interferon-alfa treatment differentially redirects mutated and wildtype hematopoietic cell differentiation trajectories in CALR-mutated essential thrombocythemia (ET) patients
    Meeting Abstract

    Rosenberg, S.; Kubas-Meyer, A.; Parghi, N.; Omans, N. D.; Dusai, N.; Chamely, P.; Mimitou, E.; Dueck, A. C.; Kosiorek, H. E.; Weinberg, R. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • "Building a more inclusive blood system in Canada": A mixed-methods evaluation of a workshop to guide medical students to develop as health advocates through advancing health equity in blood product donation for gay, bisexual, and queer men
    Meeting Abstract

    Rosenfeld, A.; Baribeau, O.; Berscheid, K.; Chan, S. W. S.; Farrokhi, K.; Herman, D.; Lee, A.; Segall, R.; Singh, N.; Wroot, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A multicenter analysis of outcomes, toxicities, and patterns of use with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas
    Meeting Abstract

    Riedell, P. A.; Brower, J.; Nastoupil, L.; Perales, M. A.; Maziarz, R. T.; McGuirk, J. P.; Bachanova, V.; Hwang, W. T.; Schuster, S. J.; Bishop, M. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save